Systematic use of a collagen-based vascular closure device immediately after cardiac catheterization procedures in 1,317 consecutive patients

被引:29
作者
Eggebrecht, H
Haude, M
Woertgen, U
Schmermund, A
von Birgelen, C
Naber, C
Baumgart, D
Kaiser, C
Oldenburg, O
Bartel, T
Kroeger, K
Erbel, R
机构
[1] Univ Hosp Essen, Dept Cardiol, Ctr Internal Med, D-45122 Essen, Germany
[2] Univ Hosp Essen, Dept angiol, Essen, Germany
关键词
vascular access complications; catheterization; closure device; femoral; bleeding; Angio-Seal;
D O I
10.1002/ccd.10254
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite recent advances in interventional cardiology, vascular access complications continue to be a significant problem. Conventional manual compression of the femoral access site is associated with prolonged immobilization and significant patient discomfort. We investigated the performance of a collagen-based closure device applied immediately after catheterization and its complication rate in 1,317 consecutive patients undergoing cardiac catheterization or coronary angioplasty. Patients undergoing coronary angioplasty (n = 644) received more heparin than patients with diagnostic cardiac catheterization (n = 673; 9,675 +/- 19144 IU vs. 6,419 +/- 2,211 IU; P < 0.0001). Deployment success rates of the closure device were comparable for patients undergoing diagnostic vs. interventional procedures (95.8% vs. 96.7%; P = 0.46). Complete hemostasis immediately after deployment of the device was achieved in > 90% of all patients, but was lower in the interventional group (93.7% vs. 90.6%; P = 0.05). Major complications including any vascular surgery, major bleeding requiring transfusion, retroperitoneal hematoma, thrombosis or loss of distal pulses, groin infections, significant groin hematoma, and death were observed in 0.53% of all patients, with no differences between diagnostic or interventional patients (0.62% vs. 0.45%; P = 0.953). Subgroup analysis revealed female gender as a predictor of access site complications. Systematic sealing of femoral access sites after both diagnostic and interventional procedures allows for immediate sheath removal with reliable hemostasis. The use of a collagen-based closure device is associated with a low rate of clinically significant complications. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:486 / 495
页数:10
相关论文
共 55 条
  • [1] BLEEDING COMPLICATIONS WITH THE CHIMERIC ANTIBODY TO PLATELET GLYCOPROTEIN IIB/IIIA INTEGRIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
    AGUIRRE, FV
    TOPOL, EJ
    FERGUSON, JJ
    ANDERSON, K
    BLANKENSHIP, JC
    HEUSER, RR
    SIGMON, K
    TAYLOR, M
    GOTTLIEB, R
    HANOVICH, G
    ROSENBERG, M
    DONOHUE, TJ
    WEISMAN, HF
    CALIFF, RM
    [J]. CIRCULATION, 1995, 91 (12) : 2882 - 2890
  • [2] IMMEDIATE ARTERIAL HEMOSTASIS AFTER CARDIAC-CATHETERIZATION - INITIAL EXPERIENCE WITH A NEW PUNCTURE CLOSURE DEVICE
    AKER, UT
    KENSEY, KR
    HEUSER, RR
    SANDZA, JG
    KUSSMAUL, WG
    [J]. CATHETERIZATION AND CARDIOVASCULAR DIAGNOSIS, 1994, 31 (03): : 228 - 232
  • [3] Ali A, 1999, AM J CARDIOL, V84, p104P
  • [4] Suture-mediated closure of the femoral access site after cardiac catheterization: Results of the suture to ambulate and discharge (STAND I and STAND II) trials
    Baim, DS
    Knopf, WD
    Hinohara, T
    Schwarten, DE
    Schatz, RA
    Pinkerton, CA
    Cutlip, DE
    Fitzpatrick, M
    Ho, KKL
    Kuntz, RE
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (07) : 864 - 869
  • [5] Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting - The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study
    Bertrand, ME
    Legrand, V
    Boland, J
    Fleck, E
    Bonnier, J
    Emmanuelson, H
    Vrolix, M
    Missault, L
    Chierchia, S
    Casaccia, M
    Niccoli, L
    Oto, A
    White, C
    Webb-Peploe, M
    Van Belle, E
    McFadden, EP
    [J]. CIRCULATION, 1998, 98 (16) : 1597 - 1603
  • [6] Vascular access site complications after percutaneous coronary intervention with abciximab in the evaluation of c7E3 for the prevention of ischemic complications (EPIC) trial
    Blankenship, JC
    Hellkamp, AS
    Aguirre, FV
    Demko, SL
    Topol, EJ
    Califf, RM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (01) : 36 - 40
  • [7] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY
    CALIFF, RM
    SHADOFF, N
    VALETT, N
    BATES, E
    GALEANA, A
    KNOPF, W
    SHAFTEL, J
    BENDER, MJ
    AVERSANO, T
    RAQUENO, J
    GURBEL, P
    COWFER, J
    COHEN, M
    CROSS, P
    BITTL, J
    EDDINGS, K
    TAYLOR, M
    DEROSA, K
    HATTEL, L
    COOPER, L
    ESHELMAN, B
    FINTEL, D
    NIEMYSKI, P
    KLEIN, L
    KENNEDY, H
    THORNTON, T
    KEREIAKES, D
    MARTIN, L
    ANDERSON, L
    HIGBY, N
    ELLIS, S
    BREZINA, K
    GEORGE, B
    CHAPEKIS, A
    SMITH, D
    ANWAR, A
    GERBER, TL
    PRITCHARD, GL
    MYLER, R
    SHAW, R
    MURPHY, M
    WARD, K
    MADIGAN, NP
    BLANKENSHIP, J
    HALBERT, M
    FLANAGAN, C
    TANNENBAUM, M
    POLICH, M
    STEVENSON, C
    TCHENG, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) : 956 - 961
  • [8] Suture closure of femoral arterial puncture sites after coronary angioplasty followed by same-day discharge
    Carere, RG
    Webb, JG
    Buller, CEH
    Wilson, M
    Rahman, T
    Spinelli, J
    Anis, AH
    [J]. AMERICAN HEART JOURNAL, 2000, 139 (01) : 52 - 58
  • [9] Cooper CL, 1999, CATHETER CARDIO INTE, V48, P301, DOI 10.1002/(SICI)1522-726X(199911)48:3<301::AID-CCD15>3.0.CO
  • [10] 2-F